Rechallenge or switching to other CDK4/6 inhibitors in HR+/HER2–metastatic breast cancer after progression
Open Access
- 30 June 2026
- journal article
- Published by Institute for Medical Radiology and Oncology of NAMS of Ukraine in Український радіологічний та онкологічний журнал
- Vol. 34 (2) , 256-268
Abstract
Background. After progression on endocrine therapy combined with palbociclib in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer, a practical question arises regarding subsequent treatment: whether it is appropriate to reuse the same cyclin-dependent kinase inhibitor with a change in the endocrine partner, whether it is more rational to switch to another agent in this class, or whether to proceed only with the next line of endocrine therapy.Purpose – to assess the clinical appropriateness of palbociclib rechallenge and the strategy of switching cyclin-dependent kinase inhibitors after progression on palbociclib in metastatic breast cancer.Materials and Methods. A narrative literature review was performed. Sources were searched in PubMed/MEDLINE, Scopus, and ClinicalTrials.gov over the last seven years (2020–2026); supplementary searches for guidelines, congress materials, and regulatory documents were performed using Google Scholar. The analysis included randomized clinical trials, meta-analyses, reviews, and current clinical guidelines addressing treatment after progression on palbociclib.Results. The analysis showed that continuing therapy with the same inhibitor, particularly palbociclib, while changing the underlying endocrine therapy does not lead to a statistically significant improvement in progression-free survival, indicating the development of stable cross-resistance and making this approach clinically unjustified. In contrast, switching to another cyclin-dependent kinase inhibitor, primarily abemaciclib or ribociclib, is associated with more stable disease control and a more favorable balance between expected benefit and risk. It was additionally established that treatment selection after progression is increasingly determined by the molecular tumor profile, because alterations in estrogen receptor signaling, the phosphatidylinositol 3-kinase cascade, and loss of function of suppressor regulators may affect sensitivity to subsequent endocrine and targeted therapy, requiring the use of newer selective estrogen receptor degraders or targeted inhibitors.Conclusions. After progression on palbociclib, preference should be given not to routine rechallenge with the same drug, but to an individualized strategy involving a change of cyclin-dependent kinase inhibitor and consideration of the molecular characteristics of the tumor.Keywords
This publication has 27 references indexed in Scilit:
- Overall survival with abemaciclib in early breast cancerAnnals of Oncology, 2025
- Cyclin-dependent kinase 4/6 inhibitors beyond progression in hormone receptor-positive, HER2-negative advanced breast cancer: a systematic review and meta-analysis (REIGNITE study)ESMO Open, 2025
- Updated treatment recommendations for systemic treatment: from the ESMO Metastatic Breast Cancer Living GuidelineAnnals of Oncology, 2025
- GAIDeT (Generative AI Delegation Taxonomy): A taxonomy for humans to delegate tasks to generative artificial intelligence in scientific research and publishingAccountability in Research, 2025
- Imlunestrant with or without Abemaciclib in Advanced Breast CancerNew England Journal of Medicine, 2025
- Resistance mechanisms and therapeutic strategies of CDK4 and CDK6 kinase targeting in cancerNature Cancer, 2025
- A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trialAnnals of Oncology, 2024
- Capivasertib in Hormone Receptor–Positive Advanced Breast CancerNew England Journal of Medicine, 2023
- Overall Survival with Ribociclib plus Letrozole in Advanced Breast CancerNew England Journal of Medicine, 2022
- The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2JAMA Oncology, 2020